Clinical trial NCT01231607
Conditions: Androgenetic Alopecia
Sponsor: GlaxoSmithKline
Start date: 2010-10-28; Completion date: 2012-02-28
Enrollment: 917 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

Detailed description:
Androgenetic alopecia is a common, androgen-induced, pattern of progressive loss of scalp hair with an onset at any age after puberty in genetically predisposed people. The influence of androgens on scalp hair growth is mediated by local and systemic conversion of testosterone to dihydrotestosterone , by the enzyme 5 alpha-reductase. 5 alpha-reductase has been shown to exist as 2 isoenzyme forms, Type 1 and Type 2. Type 1 is predominantly located in the skin, both in the hair follicles and sebaceous glands, and is also found in the liver and kidney . Type 2 is the dominant form in male genitalia, including the prostate, although it has also been reported to be present in the inner root sheath of the hair follicle. The presence of both isoenzymes in the hair follicles suggests that both forms are likely to be important in the pathogenesis and treatment of androgenetic alopecia. Inhibition of both Type 1 and Type 2 5 alpha-reductase may be expected to more effectively reduce systemic and local dihydrotestosterone levels than inhibition of either isoenzyme alone.

Finasteride is a selective Type 2 5 alpha-reductase inhibitor that is currently the only approved oral treatment for androgenetic alopecia worldwide. Dutasteride inhibits both Type 1 and Type 2 5alpha-reductase and is approved in more than 80 countries for the treatment of benign prostatic hyperplasia, and in Korea for the treatment of hair loss. Dutasteride is approximately 3 times as potent as finasteride at inhibiting Type 2 5 alpha-reductase and more than 100 times as potent at inhibiting Type 1 5 alpha-reductase.

In a Phase II double-blind, placebo-controlled clinical study (ARIA2004) conducted in the United States, dutasteride demonstrated significant increases in target area hair count, as compared with placebo, as early as 12 weeks. In a Phase III double- blind, placebo-controlled clinical study conducted in Korea, dutasteride 0.5 milligram (mg) demonstrated significant increases in target area hair count, as compared with placebo, at 24 weeks. This 6 month study is being conducted to provide additional evidence of the efficacy and safety of three doses of dutasteride (0.02, 0.1 and 0.5mg) in the treatment of androgenetic alopecia, and more specifically, to characterize the dose-response relationship in an ethnically-diverse population. Treatment arms will be equally balanced with approximately 180 per arm.

Arms: arm 1: 1mg finasteride active plus dutasteride placebo, by mouth once daily arm 2: 0.02mg dutasteride active plus finasteride placebo, by mouth once daily arm 3: 0.1mg dutasteride active plus finasteride placebo, by mouth once daily arm 4: 0.5mg dutasteride active plus finasteride placebo, by mouth once daily arm 5: 1mg finasteride placebo plus dutasteride placebo, by mouth once daily
Interventions: intervention 1: 1mg Finasteride active intervention 2: 0.02mg dutasteride intervention 3: 0.1mg dutasteride intervention 4: 0.5mg dutasteride intervention 5: Finasteride placebo intervention 6: Dutasteride placebo
Intervention descriptions: intervention 1: 1mg finasteride active, by mouth once daily intervention 2: 0.02mg dutasteride active, by mouth once daily intervention 3: 0.1mg dutasteride active, by mouth once daily intervention 4: 0.5mg dutasteride active, by mouth once daily intervention 5: finasteride placebo, by mouth once daily intervention 6: dutasteride placebo, by mouth once daily

Protocol documents: